Homology Medicines, Inc. Loss Submission Form
Company: Homology Medicines, Inc.
Ticker: (NASDAQ) FIXX
Deadline
Passed
Lead Plaintiff Deadline: May 24, 2022
Never Miss Another Deadline
Choose your preferred way to stay informed of new case launches and settlement deadlines.
Get Updates by Email
Subscribe for email notifications.
Allegations
(i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.